



<b>Name</b>	Wonseok Kang
<b>Affiliation</b>	Sungkyunkwan University School of Medicine, Samsung Medical Center
<b>Country</b>	Korea
<b>Major Field</b>	Hepatology

### Educational Background

Wonseok Kang graduated from Yonsei University with his medical degree in 2004 and completed his residency at the Department of Internal Medicine in Severance Hospital in 2009. After completing his clinical training, he pursued a Ph.D. in Medical Science and Engineering at Korea Advanced Institute of Science and Technology (KAIST) in 2013.

### Professional Experience

Wonseok Kang is an Associate Professor of Medicine at Sungkyunkwan University School of Medicine, and Adjunct Professor at Samsung Advanced Institute for Health Science and Technology (SAIHST). Currently, he serves as the Chief of Digestive Disease Center at Samsung Medical Center, Seoul, Korea.

In 2022, He spent a year as a Visiting Research Scholar at The Jackson Laboratory for Genomic Medicine and Yale School of Medicine in Connecticut, USA. After returning from his sabbatical, he is currently focusing on translational research in the field of hepatology in relation to his clinical practice.

### Main Scientific Publications

- Molecular landscape of tumor-associated tissue-resident memory T cells in tumor microenvironment of hepatocellular carcinoma. *Cell Commun Signal* 2025
- Unraveling the immune-activated tumor microenvironment correlated with clinical response to atezolizumab plus bevacizumab in advanced HCC. *JHEP Rep* 2024
- NADPH oxidase 4 deficiency promotes hepatocellular carcinoma arising from hepatic fibrosis by inducing M2-macrophages in the tumor microenvironment. *Sci Rep* 2024
- Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. *Genome Med* 2022
- Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. *Liver Cancer* 2021